Clinical Trial

MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia

Study acronym: MP101-1001
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-29
Trial Details
NCT Number NCT07492771
Lead Sponsor MicrobiotiX Co., Ltd
Conditions Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection
Enrollment 18 participants
Start Date 2026-07-25
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-28